Table 2.
Overall survival and 5-year OS depending on a Karnofsky performance status score at onset
| KPS | DA (n = 351) | OL + OA (n = 205) | AA (n = 487) | AO + AOA (n = 227) | GBM (n = 1,381) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | OS | 5 y-OS | n | OS | 5 y-OS | n | OS | 5 y-OS | n | OS | 5y-OS | n | OS | 5 y-OS | |
| 10–60 | 36 | 19.0 | 30.3% | 10 | NR | 70.0% | 99 | 17.0 | 22.8% | 31 | 102.1 | 62.4% | 506 | 12.0 | 5.6% |
| 70 | 14 | 86.1 | 63.6% | 8 | 76 | 68.6% | 72 | 24 | 25.1% | 14 | 82.1 | 72.7% | 224 | 13.1 | 5.1% |
| 80 | 51 | NR | 51.7% | 18 | NR | 72.2% | 114 | 31 | 35.2% | 39 | 110.1 | 71.0% | 279 | 15 | 5.1% |
| 90 | 100 | NR | 77.3% | 59 | NR | 92.1% | 120 | 53 | 48.0% | 59 | NR | 66.9% | 266 | 20 | 19.3% |
| 100 | 150 | NR | 90.2% | 110 | NR | 92.6% | 82 | NR | 61.6% | 84 | NR | 69.1% | 106 | 17 | 20.9% |
| 90–100 | 250 | NR | 85.4% | 169 | NR | 92.4% | 202 | 69 | 55.0% | 133 | NR | 68.2% | 372 | 19 | 19.9% |
AA: anaplastic astrocytoma, AO: oligodendroglioma, AOA: anaplastic oligoastrocytoma, DA: diffuse astrocytoma, GBM: glioblastoma, KPS: Karnofsky performance status, NR: not reached, OA: oligoastrocytoma, OL: oligodendroglioma, OS: overall survival.